Xeris Pharmaceuticals (XERS) Gets a Buy Rating from Mizuho Securities

By Carrie Williams

Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERSResearch Report) today and set a price target of $22.00. The company’s shares closed last Monday at $6.19, close to its 52-week low of $5.30.

According to TipRanks.com, Yang is a 3-star analyst with an average return of 1.1% and a 43.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Revance Therapeutics, and Nektar Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals with a $22.00 average price target.

See today’s analyst top recommended stocks >>

Based on Xeris Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $32.84 million. In comparison, last year the company had a GAAP net loss of $20.42 million.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XERS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.